How should PCNA be assessed? Total of stained cells or only the most intensely stained ones?

Autores

  • Claudio Kemp Universidade Federal de São Paulo
  • Vânia Nosé Alberti Universidade Federal de São Paulo
  • Geraldo Rodrigues de Lima Universidade Federal de São Paulo
  • Filomena Marino de Carvalho Universidade Federal de São Paulo

Palavras-chave:

Breast Cancer, Prognostic Factor, Proliferating cell nuclear antigen (PCNA/cyclin)

Resumo

Estudou-se o valor prognóstico do antígeno nuclear de proliferação celular (PCNA/Ciclina) em 59 pacientes do Estadio II (T2, N0,1, M0). As pacientes foram separadas de acordo com comprometimento dos linfonodos axilares, com dois grupos, ditos "Axila Positiva" e "Axilia Negativa". Determinou-se a presença do PCNA através do método Avidin-Biotinaperoxidase utilizando o anticorpo monoclonal PC-10. Fez-se a contagem das células no campos mais representativos e contíguos, sempre observando o número de células coradas sobre o total de células contadas, em dois conjuntos, ou seja, total de células coradas e o das mais intensamente coradas. Cotejou-se esses valores com os parâmetros, idade, tamanho do tumor, graus nuclear e histológico e o estado de envolvimento dos linfonodos axilares. Observou-se que o falso juízo e as divergências na avaliação da atividade proliferativa dos tumores podem advir da seleção das amostras, do campo escolhido para contar as células ou dos diferentes aspectos e intensidade consideradas como positivo para o PCNA. Notou-se haver significante associação com valores crescentes da ciclina e a piorea na classificação dos graus nuclear e histológico, em particular, nas pacientes que tinham axila negativa. Sob o ponto de vista prognóstico, a graduação mais elevada do grau nuclear (GN3) e do histológico (GHIII) associaram-se a altos índices de PCNA (>50) e distingüem um grupo de pacientes de alto risco; isto é particularmente importante quando as pacientes têm axila negativa e há necessidade de tratamento sistêmico quimioterápico. Verificou-se ser, essa técnica, simples, reproduzível e facilmente adaptável à rotina laboratorial.

Downloads

Não há dados estatísticos.

Biografia do Autor

Claudio Kemp, Universidade Federal de São Paulo

Universidade Federal de São Paulo, Departments of Gynecology and Pathology, São Paulo, Brazil.

Vânia Nosé Alberti, Universidade Federal de São Paulo

Universidade Federal de São Paulo, Departments of Gynecology and Pathology, São Paulo, Brazil.

Geraldo Rodrigues de Lima, Universidade Federal de São Paulo

Universidade Federal de São Paulo, Departments of Gynecology and Pathology, São Paulo, Brazil.

Filomena Marino de Carvalho, Universidade Federal de São Paulo

Universidade Federal de São Paulo, Departments of Gynecology and Pathology, São Paulo, Brazil.

Referências

Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978; 121: 2228-33.

Celis EJ, Celis A. Cell-cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S-phase. Proc Natl Acad Sci 1985; 82: 3262- 6.

Bravo R, Frank R, Blundell APP, Macdonad-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-d. Nature 1987; 326:515-17.

Garcia RL, Coltrera MD, Gown AM. Analysis of Proliferative Grade Using Anti-PCNA/Cyclin Monoclonal Antibodies in Fixed, Embedded Tissues. Am J Pathol 1989; 134: 733-39.

Hall AP, Levison AD, Woods LA, Yu WCC, Kellock BD, Watkins AJ, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285-94.

Dawlson AE, Norton JA, Weinberg DS. Comparative assessment of proliferations and DNA content in breast carcinoma by image analysis and flow cytometry. AJP 1990; 136: 1115-24.

Shrestha P, Yamada K, Wada T, Maeda S, Watatani M, Yasutomi M, et al. Proliferating cell nuclear antigen in breast lesions: correlation of c-erb B-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer. Virchows Archiv A Pathol Anat 1992; 421: 193-202.

Aaltomaa S, Lipponen P, Papinaho S, Syrjanen K. Proliferating cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer. J Cancer Rev Clin Oncol 1993; 119: 288-94.

Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, et al. Prognostic value of proliferating cell nuclear antigen in lymph node - negative breast cancer patients. Cancer 1993; 72: 120-5.

Cummings CM, Furnival MC, Parsons GP, Townsend E. PCNA immunostaining in breast cancer. Aust NZJ Surg. 1993; 63: 630-6.

Narita T, Fünahashi H, Satoh Y, Takagi H. Proliferation cell nuclear antigen immunostaining in breast cancer and its relation to prognosis. Jpm J Clin Oncol 1993; 23(1): 20-5.

Tahan RS, Neuberg SD, Dieffenbach A, Yacoub L. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 1993; 71: 3552-9.

Sullivan RP, Mortimer G, Muircheartaigh IO. Cell proliferations in breast tumor: analysis of histological parameters Ki-67 and PCNA expression. IJMS 1993; 162: 343-7.

Thomas M, Noguchi M, Kitagawa H, Kinoshija K, Miyazaki I. Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol 1993; 46: 525-8.

Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 1994; 57: 822-9.

Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63:181- 7.

World Health Organization. Histological typing of breast tumors. 2nd.ed.Geneva: WHO; 1981:106.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.

Hsu S, Raine L, Fanger H. Use for Avidin-biotin- peroxidase comparison between ABC and unlabelled antibody PAP procedures. J Histochem Cytochem 1981; 29: 557-80.

Siegel S. Estadistica no parametrica. México: Trillas; 1975: 346.

Leonardi E, Girlando S, Serio G, Mauri AF, Perrone G, Scampini S, et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 1992; 45: 416-9.

Siitonen SM, Kallioniemi O, Isola JJ - Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer. AJP 1993; 142: 1081-9.

Haerslav T, Jacobsen GK. Proliferating cell nuclear antigen in breast carcinomas: an immunohistochemical study with correlation to histopathological features and prognostic factors. Virchows Archiv 1994; 424: 39-46.

Fisher B, Redmond C, Fisher E, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjuvant breast and bowel project protocol B-06. J Clin Oncol 1988; 6: 1076-87.

Downloads

Publicado

1998-03-03

Como Citar

1.
Kemp C, Alberti VN, Lima GR de, Carvalho FM de. How should PCNA be assessed? Total of stained cells or only the most intensely stained ones?. Sao Paulo Med J [Internet]. 3º de março de 1998 [citado 16º de outubro de 2025];116(2):1667-74. Disponível em: https://periodicosapm.emnuvens.com.br/spmj/article/view/2272

Edição

Seção

Artigo Original